Table 1 Comparison of mother’s demographics, pregnancy-related, and clinical characteristics based on inclusion of Remdesivir in the treatment regimen

Age (years), median(IQR)

189

32(6)

32(7)

0.924^*

BMI (kg/m2), median (IQR)

189

28(5.5)

28(6)

0.210^*

BMI, Categories, N(%)

Normal

189

9(16.7%)

30(22.2%)

0.695^†

Overweight

24(44.4%)

56(41.5%)

Obese

21(389%)

49(36.5%)

Gravid, median (IQR)

189

2(1.25)

2(2)

0.07^*

Abortion, median (IQR)

189

0(1)

0(1)

0.78^*

Preeclampsia, N(%)

189

2(3.7%)

15(11.1%)

0.08^a

Gestational diabetes, N(%)

188

8(14.8%)

19(14.25%)

0.91^b

Abortion, N(%)

179

3(5.6%)

7(5.2%)

0.58^a

Gestational week at the onset of COVID–19 symptoms (weeks), N.(%)

First Trimester

189

3(5.6%)

4(3%)

0.532^†

Second Trimester

7(13%)

13(9.6%)

Third trimester

44(81.5%)

118(87.4%)

First SPO₂ without a mask, N.(%)

 < 94

43

15(27.8%)

28(20.7%)

0.29^†

 ≥ 94

146

39(72.2%)

107(79.3%)

Severe COVID–19, N(%)

189

15(27.8%)

28(20.7%)

0.33^†

Admission to ICU, N(%)

189

5(9.3%)

20(14.8%)

0.308^†

Intubation, N(%)

189

2(3.7%)

11(8.1%)

0.27^†

Cardiopulmonary resuscitation, N(%)

189

2(3.7%)

7(5.2%)

0.49^‡

COVID–19–related death, N(%)

189

3(5.6%)

10(7.4%)

0.46^‡

ARDS as the cause of death

189

0(0%)

5(3.7%)

0.18^‡

Hospital LOS (days), median (IQR)

189

7(4)

3(4)

 < 0.0001^*

ICU LOS (days), median (IQR)

25

4(5.5)

3(6.75)

0.65^*